TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript

TG Therapeutics reported strong Q2 2025 financial results, with U.S. net sales for its flagship multiple sclerosis drug, BRIUMVI, reaching $138.8 million, a 91% year-over-year increase, contributing to a GAAP net income of $28.2 million. The company raised its full-year 2025 U.S. net revenue guidance for BRIUMVI to $575 million, driven by robust commercial momentum, including capturing nearly one-third of new IV anti-CD20 patient prescriptions and achieving record new patient enrollments. Strategically, TG is advancing its pipeline with the imminent initiation of a pivotal Phase III trial for a subcutaneous BRIUMVI formulation, aiming to address a significant self-administered market segment, and is also progressing an enhanced IV dosing regimen and its novel CAR-T therapy, azer-cel, for progressive MS, positioning the company for sustained leadership and growth in the MS market.

Analysis

TG Therapeutics reported a strong second quarter for 2025, driven by its multiple sclerosis drug, BRIUMVI. U.S. net sales for BRIUMVI reached $138.8 million, a 91% increase year-over-year and a 16% sequential increase, contributing to a GAAP net income of $28.2 million. The company's commercial execution appears robust, having captured nearly one-third of new IV anti-CD20 patient prescriptions and seeing record new patient enrollments, supported by a new national television campaign showing early positive signs. Consequently, management raised its full-year 2025 U.S. revenue guidance for BRIUMVI to $575 million. Strategically, the company is advancing a subcutaneous (subcu) formulation of BRIUMVI, with a pivotal Phase III trial initiating shortly that aims to access the 35-40% of the anti-CD20 market preferring self-administration, targeting a potential 2028 launch. Further pipeline developments include a trial for a more convenient single-day IV infusion and the first patient dosed with its azer-cel CAR-T therapy for progressive MS. Financially, the company remains disciplined, maintaining its full-year operating expense guidance of approximately $300 million and ending the quarter with a stable cash position of $279 million.

Key Decisions for Investors

• Given the strong commercial momentum and raised revenue guidance to $575 million, investors should recognize the near-term growth potential for BRIUMVI, but also factor in management's note on Q3 seasonality, which implies more significant growth will occur in the fourth quarter.
• The planned pivotal trial for a subcutaneous version of BRIUMVI represents a significant long-term catalyst that could expand the addressable market; investors should monitor enrollment progress and clinical updates for this program, which targets a 2027 BLA filing.
• It is prudent to monitor the gross-to-net margin, which trended towards the lower end of the 70-75% annual guidance in Q2 due to sales mix, as continued shifts could impact future profitability.
• The advancement of the azer-cel CAR-T program into the clinic provides long-term pipeline optionality, but its valuation should be considered nascent and distinct from the core, de-risked BRIUMVI franchise.